The American Academy of Orthopaedic Surgeons Expands Choosing Wisely® List

The  American Academy of Orthopaedic Surgeons expanded list includes the following five recommendations:

  • Avoid routine use of Continuous Passive Motion (CPM) after knee replacement.
  • Avoid routinely performing arthroscopy with lavage and/or debridement in patients with a primary diagnosis of symptomatic osteoarthritis of the knee.
  • Do not transfuse asymptomatic postoperative hip fracture patients with a hemoglobin higher than 8g/dl.
  • Avoid routine use of therapy following carpal tunnel release.
  • Avoid routine use of opioids for treatment of knee osteoarthritis, hip osteoarthritis, low back pain, or rotator cuff injury.

“As orthopaedic surgeons, our duty to our patients is to restore mobility and improve their quality of life through evidence-based, high-quality treatment,” said Joseph A. Bosco III, MD, FAAOS, AAOS President. “Our Healthcare system is rapidly transforming into a value-based model. The Choosing Wisely initiative encourages orthopaedic surgeons and clinicians across a variety of specialties to carefully consider the value proposition of the tests and procedures they provide. Understanding the value of interventions enables surgeons to make evidence-based decisions about the most appropriate care – all while maintaining a two-way conversation with their patients.”

The Academy’s Choosing Wisely list was expanded after careful consideration and review, using the most current evidence about management and treatment options. AAOS routinely develops evidence-based clinical guidelines and appropriate use criteria as valuable tools to advance the physician-patient communications process and enhance the diagnosis and treatment of musculoskeletal conditions. Each of the recommendations now included on the list came out of those clinical practice guidelines.

“Clinicians and patients all across the United States – and now the world – are engaging in conversations about avoiding unnecessary care thanks to the efforts of medical specialty societies like the AAOS,” said Richard J. Baron, MD, president and CEO of the ABIM Foundation. “The content of the AAOS Choosing Wisely list will help further these conversations and better the future of orthopaedic patient care.”

Since the launch of the Choosing Wisely campaign in 2012, it has covered more than 600 tests and procedures that the specialty society partners say are overused and may be inappropriate, and that physicians and patients should discuss. More than 80 national medical specialty societies have released recommendations, and dozens of regional health collaboratives and consumer partners have joined the conversations about appropriate care.

To learn more, visit www.ChoosingWisely.org.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”